Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 2/20 | 0.57 |
| ▸ | PARP1 | P09874 | 2/20 | 0.52 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.52 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | IKBKB | O14920 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30821626 | 1.00 | NOS2 (0.57) | NOS2PARP1PARP10CA1CA2 | |
| Hydrochloric Acid SCHEMBL11466167 | 0.98 | NOS2 (0.56) | NOS2PARP1PARP10CA1CA2 | |
| SCHEMBL5306467 | 0.86 | IKBKB (0.65) | NOS2PARP1PARP10CA1CA2 | |
| SCHEMBL221141 | 0.85 | SMN1; SMN2 (0.59) | NOS2KDM4EALDH1A1CYP3A4MAPT | |
| SCHEMBL632502 | 0.85 | ALDH1A1 (0.59) | NOS2KDM4EALDH1A1CYP3A4MAPT | |
| SCHEMBL29923727 | 0.85 | ALDH1A1 (0.59) | NOS2KDM4EALDH1A1CYP3A4MAPT | |
| SCHEMBL29380973 | 0.85 | SMN1; SMN2 (0.59) | NOS2KDM4EALDH1A1CYP3A4MAPT | |
| SCHEMBL148855 | 0.85 | ALDH1A1 (0.53) | NOS2PARP1PARP10CA1CA2 | |
| SCHEMBL27720018 | 0.85 | SMN1; SMN2 (0.59) | NOS2KDM4EALDH1A1CYP3A4MAPT | |
| SCHEMBL25328315 | 0.84 | NR4A1 (0.52) | NOS2PARP10PARP2PARP4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 217 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122010957-A | Preparation method of fullerene pyrrolidine quinazolinone | 湖北大学 | 2026-05-12 | — | — | CN | claimed |
| CN-117820337-A | Preparation method of 12H-benzo [4,5] thiazolo [2,3-b ] quinazoline 12-ketone compound | 赣南师范大学 | 2024-04-05 | — | — | CN | claimed |
| CN-111848527-A | 4-chloro-2- (2-fluoro-4-methoxyphenyl) -6-methoxyquinazoline and synthetic method thereof | 南通大学 | 2020-10-30 | — | — | CN | claimed |
| CN-122010957-A | Preparation method of fullerene pyrrolidine quinazolinone | 湖北大学 | 2026-05-12 | — | — | CN | disclosed |
| EP-4731216-A1 | HETEROARYL-AMINE COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS | Augustine Therapeutics (BE) | 2026-04-29 | — | — | EP | disclosed |
| EP-4719394-A2 | INHIBITORS OF TYK2 | Atomwise Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260048051-A1 | TREATMENT OF INFLAMMATORY BOWEL DISEASE | ATOMWISE INC (US) | 2026-02-19 | — | — | US | disclosed |
| EP-4127157-B1 | MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS | ENCODIA INC (US) | 2026-02-11 | — | — | EP | disclosed |
| WO-2025227032-A1 | METHODS FOR DEGRADATION OF CYCLIN K AND INHIBITION OF CYCLIN DEPENDENT KINASES | REMIX THERAPEUTICS INC. (US) | 2025-10-30 | — | — | WO | disclosed |
| US-12421222-B2 | Substituted quinazolines as HDAC6 inhibitors | AUGUSTINE THERAPEUTICS (BE) | 2025-09-23 | — | — | US | disclosed |
| US-12358904-B2 | Inhibitors of TYK2 | Atomwise Inc. (US) | 2025-07-15 | — | — | US | disclosed |
| US-6608056-B1 | Phosphatidylinositol 3-kinase inhibitors and carcinostatic agents | YAMANOUCHI PHARMACEUTICAL CO., LTD (JP) | 2003-08-19 | — | — | US | disclosed |
| CN-1426398-A | Fused heteroaryl derivatives | YAMANOUCHI PHARMA CO LTD (JP) | 2003-06-25 | — | — | CN | disclosed |
| EP-1277738-A1 | CONDENSED HETEROARYL DERIVATIVES | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2003-01-22 | — | — | EP | disclosed |
| US-6479499-B1 | INHIBITORS OF TUBULIN POLYMERIZATION | NATIONAL SCIENCE COUNCIL (TW) | 2002-11-12 | — | — | US | disclosed |
| US-20020151544-A1 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2002-10-17 | — | — | US | disclosed |
| US-5030727-A | Reacting an anthronilide derivative with a thiazole derivative or a fluorozuinazolone with a neucleophile | BASF AKTIENGESELLSCHAFT (DE) | 1991-07-09 | — | — | US | disclosed |
| EP-0263523-A2 | Process for the preparation of thiazolo [2,3-b] quinazolones | BASF Aktiengesellschaft (DE) | 1988-04-13 | — | — | EP | disclosed |
| US-4400507-A | FOR COLORING POLYMERS, LACQUERS | CIBA-GEIGY CORPORATION (US) | 1983-08-23 | — | — | US | disclosed |
| US-4262120-A | YELLOW TO ORANGE SHADES OF GOOD FASTNESS | CIBA-GEIGY CORPORATION (US) | 1981-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260048051-A1 | TREATMENT OF INFLAMMATORY BOWEL DISEASE | TYK2, FRK, DYRK2 | NOS2 1750/4885PARP1 2186/4885PARP10 2377/4885 |
| US-12358904-B2 | Inhibitors of TYK2 | TYK2, LCK, JAK2 | NOS2 3388/4885PARP1 1129/4885PARP10 501/4885 |
| US-20020151544-A1 | Fused heteroaryl derivatives | PIK3CD, PIK3R3, PIK3C2A | NOS2 3761/4885PARP1 1165/4885PARP10 1139/4885 |
| US-12421222-B2 | Substituted quinazolines as HDAC6 inhibitors | HDAC6, HDAC9, HDAC1 | NOS2 3273/4885PARP1 541/4885PARP10 624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.